SCINAI IMMUNOTHERAPEUTICS LT (SCNI)
US09073Q3039 - ADR
SCINAI IMMUNOTHERAPEUTICS LT
NASDAQ:SCNI (1/14/2025, 8:04:34 PM)
After market: 3.4 -0.04 (-1.2%)3.4414
+0.02 (+0.63%)
Company Profile
Scinai Immunotherapeutics Ltd is a IL-based company operating in Biotechnology industry. Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Company Info
SCINAI IMMUNOTHERAPEUTICS LT
Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM
P: 97289302529
Employees: 31
Website: https://www.scinai.com/
SCNI News
9 days ago - Scinai Immunotherapeutics Ltd.Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and...
a month ago - Scinai Immunotherapeutics Ltd.Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc./PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
a month ago - Scinai Immunotherapeutics Ltd.Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of...
2 months ago - Scinai Immunotherapeutics Ltd.Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
2 months ago - Scinai Immunotherapeutics Ltd.Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million/PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
4 months ago - InvezzBioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire PodcastScinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is spotlighted in this week’s episode of The BioMedWire Podcast. During the episode, Scinai Immunotherapeutics CEO Amir Reichman talks with host Carmel Fisher about SCNI’s […]
SCNI Twits
Here you can normally see the latest stock twits on SCNI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
